Up and down the ladder: The latest comings and goings

Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot?

Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going, especially with all the ongoing layoffs. Despite the downsizing, there is movement.

Here is our regular feature in which we highlight a different person each week. This time around, we note that Avanir Pharmaceuticals hired Dr. Richard Malamut as senior vice president, R&D, and chief medical officer. Previously, he was senior vice president of global clinical development at Teva Pharmaceutical Industries, and has also worked at Bristol-Myers Squibb, AstraZeneca and Shire Pharmaceutical.

Cornerstone Pharmaceuticals hired Dr. Brian Mullaney as chief medical officer;

MyoKardia hired Dr. Marc Semigran as chief medical officer;

Pfizer named Kirsten Lund-Jurgensen as executive vice president and president of global supply, succeeding Anthony Maddaluna, who is retiring;

Actinium Pharmaceuticals hired Gregory Bergonio as director of clinical operations;

Addex Therapeutics hired Dr. Roger Mills as chief medical officer;

Scholar Rock hired Alan Buckler as chief scientific officer;

Otonomy hired Kathie Bishop as chief scientific officer;

Paragon Bioservices hired Ruby Hofmann as vice president of human resources and organizational development;

Paragon Bioservices hired John Conner as senior vice president, GMP manufacturing;

Taro Pharmaceutical named Uday Baldota as chief executive officer;

KalVista Pharmaceuticals hired Edward Feener as chief scientific officer;

C3 Jian hired David Goesling as vice president, finance & accounting;

Strongbridge Biopharma promoted Dr. Fredric Cohen to chief medical officer;

Nohla Therapeutics hired Shelly Heimfeld as executive vice president of research and manufacturing.